<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19246980</PMID>
      <DateCompleted>
        <Year>2009</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1720-8386</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2008</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of endocrinological investigation</Title>
          <ISOAbbreviation>J Endocrinol Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.</ArticleTitle>
        <Pagination>
          <StartPage>1119</StartPage>
          <EndPage>1123</EndPage>
          <MedlinePgn>1119-23</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Dopamine agonists have been associated with increased risk of cardiac valve regurgitation in patients with Parkinson's disease. Whether these drugs might be harmful for patients with hyperprolactinemia is still unsettled. Occasional case reports and 7 studies on the relationship between cabergoline and cardiac valve regurgitation have been published so far. Overall, cabergoline has been considered a safe therapy, although some studies suggested an increased prevalence of cardiac valve regurgitation. The aim of this meta-analysis was to assess the effects of cabergoline on cardiac valve regurgitation. Eligible studies were all trials using cabergoline in patients with either tumor or non-tumor hyperprolactinemia. Our search was updated to October 2008. Pooled data from the 6 selected studies showed that treatment with cabergoline was associated with increased risk of tricuspid valve regurgitation (fixed effects: prevalence ratio=1.40; 95% confidence interval: 1.17-1.67); on the contrary, patients treated with cabergoline and control subjects did not differ in prevalence of aortic or mitral valve regurgitation. This meta-analysis shows that patients with hyperprolactinemia treated with cabergoline are at increased risk of regurgitation of the tricuspid valve. However, regurgitation was only an echocardiographic finding since no patient had symptoms of valvular disease. This meta-analysis underscores that echocardiography is recommended in all patients with hyperprolactinemia who are candidate to be treated with or are under cabergoline therapy; monitoring cardiac valves is also recommended although precise follow- up for these patients will be likely provided by future longitudinal studies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bogazzi</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy. f.bogazzi@endoc.med.unipi.it</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manetti</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raffaelli</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lombardi</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rossi</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martino</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>J Endocrinol Invest</MedlineTA>
        <NlmUniqueID>7806594</NlmUniqueID>
        <ISSNLinking>0391-4097</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001021" MajorTopicYN="N">Aortic Valve</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004873" MajorTopicYN="N">Ergolines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006349" MajorTopicYN="N">Heart Valve Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006966" MajorTopicYN="N">Hyperprolactinemia</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008943" MajorTopicYN="N">Mitral Valve</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014261" MajorTopicYN="N">Tricuspid Valve</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>17</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2009</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19246980</ArticleId>
        <ArticleId IdType="doi">10.1007/BF03345662</ArticleId>
        <ArticleId IdType="pii">5863</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Control Clin Trials. 1986 Sep;7(3):177-88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3802833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Circulation. 2007 Dec 11;116(24):2860-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18071089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Endocrinol. 2008 Oct;159(4):R11-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18625690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Soc Echocardiogr. 2003 Jul;16(7):777-802</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12835667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2007 Jan 4;356(1):29-38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17202453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Circulation. 2000 Dec 5;102(23):2836-41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11104741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo Clin Proc. 2003 Jun;78(6):730-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12934784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2007 Jan 4;356(1):39-46</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17202454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2008 Sep;93(9):3348-56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18559921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2009;12(3):153-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18594989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2008 Oct;93(10):3777-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18682513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):200-10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16932285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2009 Jan;70(1):104-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19128367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Pharmacol. 2000 Jan;57(1):75-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10617681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Clin Pract. 2008 Dec;62(12):1864-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18462372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mov Disord. 2007 Oct 15;22(13):1936-42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17659636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Endocrinol. 2008 Jul;159(1):1-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18456868</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
